Therefore, to ensure that the methylation changes seen across renal cancers were not due to the confounding effect of VHL and other mutations, we selected a group of pan-negative WT samples by excluding samples with VHL, BAP1, or PBRM1 mutations. This evidence concerns the gene PBRM1 and renal carcinoma.